Binding of trastuzumab to the external domain of HER2 receptor prevents HER2 homo- and heterodimerization and leads to disruption of downstream HER2 signaling pathways, blocking proliferation of the breast cancer cells [3,5,6,7]. This evidence concerns the gene ERBB2 and breast cancer.